Please leave your details to download the selected poster.

InnoSIGN’s Comprehensive Pathway Analysis (CPA) platform unlocks the true value next generation sequencing (NGS) to revolutionize how patients are diagnosed, stratified, and treated.

How InnoSIGN can benefit you

  • Applications

    • New patient stratification + subtyping
    • Therapy response prediction
    • Resistance mechanism identification
    • Combination therapy opportunities
    • Discovery / preclinical insights
  • Benefits

    • Deeper, more actionable analysis of available patient data (RNA-seq)
    • Faster and optimized therapy selection
    • Better and more durable patient outcomes
    • Reduced wasted spend on failed treatments